Board Of Directors
Terry Heiman-Patterson, MD (President)
Dr. Terry Heiman-Patterson is Director of Neurodegenerative Disorders at Temple University. She is also the Director of the MDA/ALS Center of Hope, including the clinical and laboratory research programs, and active with the Northeast ALS Consortium. A leader in her field, she has published more than 90 papers, abstracts, and chapters on ALS and related motor neuron diseases. She has dedicated her career to optimizing clinical care for PALS and conducting research toward a treatment and cure.
Lawrence Corrigan (Vice President)
Larry Corrigan serves as the Vice President of the ALS Hope Foundation Board of Directors. After losing his brother Tom to ALS in 2009, Larry became involved with ALS Hope. He currently serves as a member of the Out and Back Run, a key fundraising event for the ALS Hope Foundation. Larry is employed by Shire, PLC where he is responsible for commercial data analytics for rare disease therapies. He presently resides in West Chester, PA, with his wife Jenny and their three boys, Will, Patrick, and Brendan.
Michael McCool (Treasurer)
Michael McCool became involved with the ALS Hope Foundation after losing his wife, Phyllis, to ALS. He joined the Board of Directors and has served as Treasurer and Chairman of the Finance and Development Committees since 2013. He is the owner of Michael McCool, CFO For Hire, LLC, consulting to project oriented industries for over 13 years. He specializes in small to medium sized businesses in the construction and professional services markets. McCool is an honors graduate of Temple University with a degree in Accounting. He also attended the University Of Virginia Darden School Of Business Executive Program. He is a licensed CPA in Pennsylvania. McCool's work has been published in several professional publications, and he has conducted seminars at various professional events, including Associated Builders & Contractors (ABC) and NAHB.
Mary Abood, PhD
Mary E. Abood, Ph.D. is a professor at the Department of Anatomy & Cell Biology, Center for Substance Abuse Research, at the Lewis Katz School of Medicine at Temple University. Dr. Abood's laboratory is investigating recently discovered endogenous compounds called the endocannabinoids and their cellular receptors. The endocannabinoid system is thought to play a role in addiction, pain control, motor control, learning, and memory, as well as in regulating immune function and bone growth. Her lab has cloned the CB1 and CB2 cannabinoid receptors and identified some of the structural and concomitant functional features of these proteins. These efforts have led to the identification of GPR55 and GPR18 as two putative cannabinoid receptors. On July 2, 2015, Dr. Mary Abood was awarded the Mechoulam Award for Outstanding Contributions to the Field at the 25th Annual Symposium of the International Cannabinoid Research Society. The Mechoulam award is given to a distinguished established scientist who has made continued meritorious, significant, and widely recognized contributions to cannabinoid and endocannabinoid research that have moved the discipline forward. Dr. Raphael Mechoulam, Professor, Hebrew University of Jerusalem, isolated and solved the structure of delta-9-tetrahydrocannabinol (∆9-THC), the principal psychoactive component of cannabis, in 1964. In 1992, his group isolated the first endocannabinoid (anandamide, from the Sanskrit word for bliss).
Walter Korn is a retired Engineering Manager with General Electric and Lockheed Martin Aerospace. He and his now deceased wife became involved with the ALS Hope Foundation Board when a very close friend of theirs, Al Abramson, was diagnosed with ALS. Walter currently serves on the personnel committee of the Board.
Ronald J. Patterson, Esq
Ron is an attorney and partner in Philadelphia law firm Klehr Harrison Harvey Branzburg LP, and is Co-Chair of the firm’s Land Use and Zoning Department. Ron specializes in zoning and land use law, representing an array of real estate developers and business operators in the Philadelphia area. His practice also involves interaction with local politicians and community civic groups. Ron also holds a chemical engineering degree from Drexel University, and has experience in environmental engineering, regulatory and permitting in the areas of air pollution contaminants and hazardous substances. Ron has a personal interest in the enhancement of the awareness, fundraising, clinical services of the Foundation, and the treatment of ALS patients.
Gary Romano, MD, PhD
Gary is the Head of Clinical Development for Alzheimer’s disease and Neurology at Janssen R&D (Johnson & Johnson). Prior to his present appointment, Gary held other leadership positions at Janssen, including head of the neuroscience biomarkers, and head of early clinical development. Gary received his Ph.D. in Molecular Neurobiology from the Rockefeller University, and his M.D. from the Johns Hopkins University School of Medicine. He completed his post-graduate training in neurology and neuromuscular disease at the University of Pennsylvania. He was a Phi Beta Kappa graduate of Trinity College, Hartford and is the author of numerous refereed articles and textbook chapters. He currently holds an adjunct faculty position in the department of Neurology at Drexel University College of Medicine in Philadelphia, is an industry co-leader of the European Prevention of Alzheimer’s disease research initiative, and was the industry co-chair of the Coalition Against Major Diseases from 2011-13. Gary is a Board Member of the ALS Hope Foundation and Alpine Home Care.
Deborah Santarpio Stanfa
Deborah has served on the ALS Hope Foundation Board of Directors since 2003, after her brother died of ALS. She worked in the medical field for quite some time, licensed in radiology and ultrasonography. She also worked as the controller of a concrete and concrete pumping business for commercial properties. She has done property management along with buying and selling real estate, including large commercial properties. She was property and rental manager of condominium complexes that she and her brother built in various seashore areas. She is currently Financial Chair and Lay Member of the United Methodist Church and a licensed cosmetologist. She has an insurance and financial services company in New Jersey as she continues to lease and sell various properties.
Mary Kay Turner
Mary Kay Turner has spent her professional career in the biopharma industry in Government Affairs, Advocacy and Health policy. Her most recent position was the head of Public Affairs for Mitsubishi Tanabe Pharma America leading the commercialization of a compound for ALS (Amyotrophic Lateral Sclerosis). She is a government affairs executive with political action and legislative/advocacy /regulatory expertise.
Mary Kay’s most rewarding experiences throughout her career have been in working in areas of high unmet medical need. During her work in ALS, she was struck by the people and caregivers she met with ALS. She is inspired by the healthcare practitioners and researchers who have dedicated their lives to changing the course for this devastating condition.
In 2016, Mary Kay was appointed to the Arizona Biomedical research Commission by Government Doug Ducey and served a one-year term. She is also on the Board of Advisers for the International Cancer Advocacy Network. Prior, Mary Kay served on the Board of Directors for Mental Health America for 5 years. Mary Kay has a Bachelor of Arts degree in Political Science and History from the University of Oregon.